Fisher & Paykel Healthcare Corporation Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FSPKF research report →
About the company
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, specializes in the global development, manufacturing, marketing, and distribution of sophisticated medical device products and systems. The company's offerings are crucial for acute and chronic respiratory care, surgical support, and the management of obstructive sleep apnea (OSA) in both clinical and home environments. Its product portfolio features advanced solutions such as the Airvo 2 humidified high-flow nasal system, Optiflow nasal high-flow therapy, and the F&P 850 System for both non-invasive and invasive ventilation.
- CEO
- Lewis G. Gradon
- IPO
- 2001
- Employees
- 6,978
- HQ
- Auckland, NZ
Price Chart
- Market Cap
- $13.23B
- P/E
- 49.64
- P/S
- 9.97
- P/B
- 11.02
- EV/EBITDA
- 28.17
- Div Yield
- 1.54%
- Gross Margin
- 64.16%
- Op Margin
- 28.52%
- Net Margin
- 20.03%
- ROE
- 22.84%
- ROIC
- 20.72%
- Revenue
- $2.36B · 84.52%
- Net Income
- $473.20M · 25.45%
- EPS
- $0.81 · 26.56%
- Op Income
- $673.69M
- FCF YoY
- 11.16%
- 52W High
- $25.69
- 52W Low
- $16.35
- 50D MA
- $21.51
- 200D MA
- $20.84
- Beta
- 0.89
- Avg Volume
- 311
Get TickerSpark's AI analysis on FSPKF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our FSPKF coverage
Recent articles, reports, and earnings notes.
No research on FSPKF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FSPKF report →Similar companies
Peers in the same neighborhood.